AOD-9604 complete guide

AOD-9604 (sometimes written AOD9604, “Anti-Obesity Drug 9604”) is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone — residues 176-191 of the 191-residue parent hormone, with an additional N-terminal tyrosine appended for stability. The compound is the product of a deliberate research program. In the 1990s, Frank Ng and colleagues at Monash University (Australia) hypothesised that the lipolytic activity of growth hormone could be separated from its somatogenic, growth-promoting activity by isolating the discrete C-terminal region in which earlier biochemical work had localised in vitro fat-cell effects. Fragment 176-191 retained measurable lipolytic activity in research-cell-line and research-animal models without driving the IGF-1-axis elevation, organ overgrowth, or insulin-resistance signal that limit GH itself.

That mechanism was the point. AOD-9604 was developed commercially by Metabolic Pharmaceuticals (Australia) as an obesity-research candidate and progressed through phase 1 and phase 2 human clinical trials in the 2000s. The compound completed a phase 2b obesity trial; published reports indicate that despite proof-of-mechanism in research models, the human trial did not meet its primary efficacy endpoints for clinically-meaningful weight loss versus placebo. The compound was subsequently reformulated and re-investigated for osteoarthritis, leveraging a smaller cartilage-research line — that program also did not advance to approval. Frame this honestly: AOD-9604 is a real research compound with a real, well-defined mechanism and a substantial published literature; it is not approved as a drug in any jurisdiction, and the commercial drug-development pipeline did not succeed. What remains is a research-only context in which the lipolytic-without-somatogenic mechanism is the relevant scientific question.

Quick reference — AOD-9604 identifiers

Property	AOD-9604
Class	Synthetic GH C-terminal fragment 176-191
Synonyms	AOD9604, Anti-Obesity Drug 9604, hGH 176-191 (with N-terminal Tyr)
Sequence (16 aa, with disulfide bridge)	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (disulfide bridge between Cys7 and Cys14; N-terminal Tyr added vs native sequence for stability)
Molecular formula	C78H123N23O23S2
Molecular weight	1815.06 g/mol
CAS number	221231-10-3
Origin	Rationally-designed fragment of native hGH; developed by Metabolic Pharmaceuticals based on Monash University research (Frank Ng et al.)
Plasma half-life (research models)	~30 minutes (short)
Vial strengths (TogoPeptide)	5 mg lyophilized

Origin and structure — the lipolytic GH fragment

Native human growth hormone is a 191-amino-acid single-chain protein with multiple distinct functional regions distributed across its sequence. Decades of structure-activity research established that the N-terminal and central regions drive the canonical somatogenic effects: GH-receptor binding, JAK2/STAT5 activation, hepatic IGF-1 transcription, anabolic signaling, and the tissue-growth phenotype. Earlier biochemical work also localised a separable lipolytic activity to the C-terminal region — adipocyte assays demonstrated that proteolytic fragments containing residues approximately 172-191 could stimulate lipolysis in vitro without engaging the somatogenic cascade with the same potency.

Frank Ng’s group at Monash hypothesised that this functional separation could be exploited synthetically. If the C-terminal lipolytic determinants could be isolated as a stable peptide, the resulting compound would in principle stimulate fat-cell lipolysis while bypassing the IGF-1-axis and growth signaling that constitute GH’s main risk profile. AOD-9604 is the result. The 16-residue sequence corresponds to native hGH 176-191, with two design-choice details: a tyrosine residue added at the N-terminus for synthetic and metabolic stability, and the disulfide bridge between the two internal cysteines (Cys7 and Cys14 in the AOD-9604 numbering) preserved to maintain the native conformational loop. The molecular weight is 1815 Da — roughly 9% of the parent hormone’s 22 kDa.

Within the broader GH-axis research family, AOD-9604 occupies a distinct niche position:

• GHRH analogs (Sermorelin, Tesamorelin, CJC-1295) — act upstream of GH, binding pituitary GHRH receptors to drive endogenous GH release. Activate the full somatogenic + IGF-1 axis.
• GHRPs (Ipamorelin, GHRP-2, GHRP-6) — act on the parallel ghrelin/GHS-R pathway. Also drive endogenous GH release; same downstream axis.
• AOD-9604 — does not engage the GH receptor, does not drive endogenous GH release, and does not activate the IGF-1 axis. It is a fragment of the parent hormone retaining only the lipolytic determinants. Mechanistically distinct from every other GH-axis research compound.

Mechanism — lipolytic without somatogenic effects

Adipocyte lipolysis stimulation

The published research literature consistently documents AOD-9604 stimulating lipolysis in adipocyte research-cell lines and adipose-tissue research-animal models. The pharmacodynamic readouts are increased free-fatty-acid (FFA) release into culture media, increased glycerol release as a complementary lipolysis marker, and decreased lipogenesis as measured by reduced incorporation of labeled glucose into triglyceride. In ob/ob and diet-induced-obese research-mouse models, chronic administration produces measurable reductions in adipose-tissue mass and increases in fat oxidation. The originating research-mouse paper (Heffernan et al., 2001) is foundational to this research line.

Mechanistically, two pathways are described in the published work. First, partial activation of the beta-3 adrenergic-receptor pathway in some research-cell-line studies, with downstream cAMP elevation and hormone-sensitive lipase (HSL) phosphorylation. Second, direct effects on HSL activation and adipose-tissue gene expression consistent with a lipolysis-promoting transcriptional program. The full receptor pharmacology of AOD-9604 has not been resolved with the same clarity as GHRHR or GHS-R — the published mechanism is described as a hybrid rather than a single canonical receptor cascade.

Reduced or absent somatogenic effects

This is the design payoff and the most consistently-reproduced feature of the published mechanism. Across research-cell-line and research-animal studies, AOD-9604 administration does not activate the GH receptor in classical somatogenic assays, does not drive measurable elevation in serum IGF-1 in research-animal models, does not produce organ overgrowth, and does not generate the insulin-resistance signal observed with sustained GH or supraphysiological GH-axis activation. The lipolytic activity is decoupled from the GH-axis effects that limit native GH and that define the pharmacology of GHRH/GHRP analogs.

No IGF-1 axis activation

This is the diagnostic mechanistic difference between AOD-9604 and the rest of the GH-axis research compound family. Sermorelin, Tesamorelin, CJC-1295, Ipamorelin, MK-677 and every other compound that acts on the upstream GH-secretion machinery produces a measurable elevation in serum IGF-1 as the integrated pharmacodynamic marker of sustained GH-axis engagement. AOD-9604 administration in published research-animal models does not produce this IGF-1 elevation. Where IGF-1 is the canonical PD marker for the GHRH/GHRP family, it is the canonical negative marker for AOD-9604: its absence is the signature of lipolytic-without-somatogenic engagement.

Beta-3 adrenergic receptor pathway research

A subset of the published mechanistic literature implicates the beta-3 adrenergic receptor in AOD-9604's lipolytic effect. Beta-3 AR is the predominant adrenergic receptor on white-adipose tissue in some species and a major endogenous driver of lipolysis. The proposed mechanism involves AOD-9604 either directly modulating beta-3 AR signaling or sensitising the downstream cAMP/HSL cascade. This partly explains why a non-GH-receptor-engaging fragment can still produce robust adipose-tissue effects: the lipolytic machinery downstream of beta-3 AR is intact and apparently accessible to fragment-induced signaling. The research is not fully resolved at the structural level — receptor-binding studies of AOD-9604 are less complete than for canonical GH-axis ligands.

Adipose-research literature

The published research-cell-line and research-animal-model literature on AOD-9604 covers three main endpoint categories. Lipolysis assays in 3T3-L1 adipocytes and primary adipose-tissue cultures document FFA and glycerol release, reduced lipogenic gene expression, and HSL activation downstream of compound exposure. Body-composition outcomes in research-mouse models (ob/ob, diet-induced-obese, lean control comparisons) document fat-mass reduction without lean-mass loss, with chronic administration over multi-week protocols. Metabolic-rate measurements via indirect calorimetry document increased fat oxidation as a percentage of substrate utilization, consistent with the lipolysis-driven phenotype.

Frame this as research-model outcomes. The literature characterises a real, reproducible compound effect in laboratory contexts. It is not a basis for therapeutic claim or extrapolation to clinical use — that translation is precisely what failed in the clinical-trial program described below.

Clinical-trial history (honest framing)

This section frames the AOD-9604 development program honestly because the public research record requires it. Metabolic Pharmaceuticals advanced AOD-9604 through standard preclinical and early-clinical research in the late 1990s and 2000s. Phase 1 studies established acceptable tolerability (Stier et al., 2013, summarises the safety dataset for the hexadecapeptide in humans). The compound progressed to phase 2 and phase 2b obesity trials in the mid-2000s, designed to test whether the proof-of-mechanism observed in research-animal models would translate into clinically-meaningful weight loss in human obesity cohorts.

The published reports indicate that the phase 2b trial did not meet its primary efficacy endpoints versus placebo. The mechanism worked in research models; the clinical translation did not deliver a magnitude of effect sufficient to support a regulatory filing as an obesity drug. The compound was subsequently reformulated by the developer and investigated for osteoarthritis, drawing on a smaller research line documenting cartilage and chondrocyte effects in research models. That second program also did not advance to approval at any agency.

The honest summary is this: the underlying research literature is real, the mechanism is well-defined and reproducible in research-model contexts, and the safety profile in early human studies was unremarkable. The commercial drug-development pipeline simply did not deliver clinical efficacy at the magnitude required for approval. AOD-9604 is consequently not an approved drug anywhere in the world. Its continuing relevance is to research-only contexts, where the lipolytic-without-somatogenic mechanism is itself the scientific question of interest — distinct from any therapeutic framing.

Cartilage-research line

A secondary published research line documents AOD-9604 effects in cartilage and chondrocyte research models. This corpus is smaller than the fat-loss research line but is what drove the developer’s later osteoarthritis pivot. The research-model work describes effects on chondrocyte gene expression, cartilage-matrix markers, and joint-tissue endpoints in research-animal models of induced osteoarthritis. As with the lipolytic literature, this is research-frame characterisation; the clinical translation in late-stage trials did not succeed, and AOD-9604 is not an approved osteoarthritis therapy.

AOD-9604 vs GLP-1 agonists vs GH/GHRH compounds — three fat-loss mechanism classes

Mechanism class	Example compound	Primary mechanism	Research framing
Incretin / GLP-1	Semaglutide, Tirzepatide, Retatrutide	GLP-1 receptor agonism — appetite suppression + glucose handling	Mainstream fat-loss research line; large clinical literature
GH-axis	Tesamorelin, Sermorelin, CJC-1295	GHRH receptor → endogenous GH release → IGF-1 elevation + lipolysis	Visceral-fat + body-composition research
GH fragment / lipolytic	AOD-9604	C-terminal GH fragment 176-191 — direct adipose lipolysis without somatogenic GH-axis activation	Lipolysis-isolated research; failed late-stage clinical translation

Position AOD-9604 as occupying a unique research-niche position. It is not a GLP-1 agonist, not a GHRH analog, not a GHRP. The mechanism is the synthetic-fragment isolation of one specific arm of native GH biology, with a corresponding distinct pharmacological signature. For research designs that want to dissect lipolysis from incretin effects or from full GH-axis activation, AOD-9604 is the closest available tool. For research-frame readers asking “is this another GLP-1 alternative?” — the answer is no, the mechanism is fundamentally different and the clinical-translation track record is fundamentally different.

Storage and handling

AOD-9604 ships as lyophilized powder. Standard research-handling literature for short cysteine-containing peptides documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window under proper storage.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent. The benzyl alcohol enables multi-puncture access across the refrigerated reconstituted shelf life.
• Reconstituted state: refrigerate at 2–8°C immediately after reconstitution. Research-handling literature documents an approximate 28-day reconstituted shelf life under refrigeration.
• Disulfide-bridge sensitivity. AOD-9604 contains an internal disulfide bridge between Cys7 and Cys14. This bridge is sensitive to repeated freeze-thaw cycles and to reducing agents (DTT, beta-mercaptoethanol, high-concentration cysteine in the diluent). Avoid freeze-thaw after reconstitution, avoid reducing buffers, and avoid prolonged exposure to elevated pH. Disulfide reduction unfolds the active conformation.
• Vial inspection: clear, colorless solution after reconstitution. Cloudiness or particulates indicate aggregation or microbial compromise; discard and re-reconstitute fresh.

Each TogoPeptide AOD-9604 shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date and analysis date. See how to read a COA or reconstitution methodology for handling-protocol details.

Cross-research lines and pairings

AOD-9604 fits naturally into the broader Fat Loss research category alongside compounds with mechanistically-different fat-loss pathways. Common research-design pairings:

• AOD-9604 + GH-axis comparison designs — pairing AOD-9604 with Tesamorelin or a GHRH/GHRP combination in parallel research arms allows direct dissection of the lipolytic contribution (AOD-9604) from the IGF-1-axis contribution (GHRH analogs) within the same experimental framework. The IGF-1 readout differentiates the two arms unambiguously.
• AOD-9604 + GLP-1 agonist comparison designs — pairing AOD-9604 with Semaglutide or another GLP-1 agonist isolates direct adipose lipolysis from appetite-driven energy-intake reduction. Body-composition versus food-intake readouts separate the two mechanisms.
• Fat Loss research category — see the Fat Loss category listing for the full research-compound set, and the Fat Loss Stack for curated multi-mechanism research bundles.
• Reconstitution standardisation — use the reconstitution calculator for stock-solution preparation when standardising concentration across research arms; AOD-9604's small size and disulfide-bridge sensitivity make accurate concentration handling especially important.

Closing

AOD-9604's research position is well-defined and mechanistically interesting — and the framing must remain honest. It is a real research compound with a real, reproducible published mechanism: a synthetic 16-residue fragment of native GH that retains lipolytic activity while decoupling from the somatogenic IGF-1-axis. It is not an approved drug: the phase 2b obesity program did not meet its primary efficacy endpoints, and the subsequent osteoarthritis-research pivot also did not advance to approval. The published literature is real; the commercial drug-development pipeline did not succeed. What remains is the research-only context in which the lipolytic-without-somatogenic mechanism is itself the question of interest.

This guide documents what published peer-reviewed research has investigated. It is structural and mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, and not a basis for self-administration of any kind.

Source AOD-9604 for laboratory research:

• AOD-9604 product page — full identifiers, 5 mg vial, per-batch COA
• Fat Loss research compounds — full category listing
• Fat Loss Stack — curated multi-mechanism research bundle

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.